Plasma sRAGE levels strongly associate with centrilobular emphysema assessed by HRCT scans
© 2022. The Author(s)..
BACKGROUND: There is a strong need for biomarkers to better characterize individuals with COPD and to take into account the heterogeneity of COPD. The blood protein sRAGE has been put forward as promising biomarker for COPD in general and emphysema in particular. Here, we measured plasma sRAGE levels using quantitative LC-MS and assessed whether the plasma sRAGE levels associate with (changes in) lung function, radiological emphysema parameters, and radiological subtypes of emphysema.
METHODS: Three hundred and twenty-four COPD patients (mean FEV1: 63%predicted) and 185 healthy controls from the COPDGene study were selected. Plasma sRAGE was measured by immunoprecipitation in 96-well plate methodology to enrich sRAGE, followed by targeted quantitative liquid chromatography-mass spectrometry. Spirometry and HRCT scans (inspiration and expiration) with a 5-year follow-up were used; both subjected to high quality control standards.
RESULTS: Lower sRAGE values significantly associated with the presence of COPD, the severity of airflow obstruction, the severity of emphysema on HRCT, the heterogeneous distribution of emphysema, centrilobular emphysema, and 5-year progression of emphysema. However, sRAGE values did not associate with airway wall thickness or paraseptal emphysema.
CONCLUSIONS: Rather than being a general COPD biomarker, sRAGE is especially a promising biomarker for centrilobular emphysema. Follow-up studies should elucidate whether sRAGE can be used as a biomarker for other COPD phenotypes as well.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Respiratory research - 23(2022), 1 vom: 24. Jan., Seite 15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klont, Frank [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 21.03.2022 Date Revised 21.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-022-01934-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336084463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336084463 | ||
| 003 | DE-627 | ||
| 005 | 20231225231330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-022-01934-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336084463 | ||
| 035 | |a (NLM)35073932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klont, Frank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma sRAGE levels strongly associate with centrilobular emphysema assessed by HRCT scans |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2022 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: There is a strong need for biomarkers to better characterize individuals with COPD and to take into account the heterogeneity of COPD. The blood protein sRAGE has been put forward as promising biomarker for COPD in general and emphysema in particular. Here, we measured plasma sRAGE levels using quantitative LC-MS and assessed whether the plasma sRAGE levels associate with (changes in) lung function, radiological emphysema parameters, and radiological subtypes of emphysema | ||
| 520 | |a METHODS: Three hundred and twenty-four COPD patients (mean FEV1: 63%predicted) and 185 healthy controls from the COPDGene study were selected. Plasma sRAGE was measured by immunoprecipitation in 96-well plate methodology to enrich sRAGE, followed by targeted quantitative liquid chromatography-mass spectrometry. Spirometry and HRCT scans (inspiration and expiration) with a 5-year follow-up were used; both subjected to high quality control standards | ||
| 520 | |a RESULTS: Lower sRAGE values significantly associated with the presence of COPD, the severity of airflow obstruction, the severity of emphysema on HRCT, the heterogeneous distribution of emphysema, centrilobular emphysema, and 5-year progression of emphysema. However, sRAGE values did not associate with airway wall thickness or paraseptal emphysema | ||
| 520 | |a CONCLUSIONS: Rather than being a general COPD biomarker, sRAGE is especially a promising biomarker for centrilobular emphysema. Follow-up studies should elucidate whether sRAGE can be used as a biomarker for other COPD phenotypes as well | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COPD biomarkers | |
| 650 | 4 | |a CT phenotyping | |
| 650 | 4 | |a Emphysema | |
| 650 | 4 | |a sRAGE | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Receptor for Advanced Glycation End Products |2 NLM | |
| 700 | 1 | |a Horvatovich, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Bowler, Russell P |e verfasserin |4 aut | |
| 700 | 1 | |a van Rikxoort, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Charbonnier, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Kwiatkowski, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Bischoff, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Ten Hacken, Nick H T |e verfasserin |4 aut | |
| 700 | 1 | |a Pouwels, Simon D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 23(2022), 1 vom: 24. Jan., Seite 15 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g day:24 |g month:01 |g pages:15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-022-01934-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 1 |b 24 |c 01 |h 15 | ||